AbbVie has released the results of a study that confirmed the efficacy of Skyrizi to improve the skin of patients with moderate to severe plaque psoriasis and their quality of life.

The company said it published the outcome of the phase-3, open-label extension LIMMitless study at the European Academy of Dermatology and Venereology (EADV) online meeting on Thursday.

According to AbbVie, two thirds (63 percent) of patients with moderate to severe plaque psoriasis treated with Skyrizi achieved the Psoriasis Area and Severity Index (PASI) 100 over three years. PASI 100 means patients’ skins had 100 percent improvement from baseline of the PASI.

After more than three years of treatment with Skyrizi, 88 percent of patients achieved clear or almost clear skin or PASI 90.

The study also found that Skyrizi positively impacted the patients’ quality of life, based on a separate analysis of the Dermatology Life Quality Index (DLQI), AbbVie said.

DLQI measures a patient's health-related quality of life, ranging from 0 to 30, with lower scores indicating the disease has less impact on life quality.

After getting treated with Skytizi for over three years, 85 percent of the patients achieved a DLQI score of 0 or 1. This meant that they showed improvement in the quality of life. Also, 91 percent of the patients had a reduction in DLQI score by at least four points, which was clinically meaningful. The proportion of patients having this reduction was consistent from one year to three years.

Boehringer Ingelheim and AbbVie developed Skyrizi jointly, and AbbVie is leading global development and sales of the product.